Concepts (194)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Community-Acquired Infections | 14 | 2023 | 87 | 3.560 |
Why?
|
| Pneumonia | 11 | 2024 | 263 | 2.660 |
Why?
|
| Anti-Bacterial Agents | 18 | 2023 | 711 | 1.460 |
Why?
|
| Pneumonia, Bacterial | 6 | 2019 | 86 | 1.380 |
Why?
|
| Cross Infection | 7 | 2020 | 150 | 1.350 |
Why?
|
| Influenza, Human | 6 | 2022 | 187 | 1.330 |
Why?
|
| Universal Precautions | 2 | 2023 | 3 | 1.040 |
Why?
|
| Guideline Adherence | 4 | 2017 | 295 | 1.040 |
Why?
|
| Pandemics | 9 | 2024 | 603 | 1.030 |
Why?
|
| Staphylococcal Infections | 2 | 2020 | 112 | 0.930 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 3 | 2021 | 64 | 0.880 |
Why?
|
| Hand Disinfection | 2 | 2014 | 14 | 0.880 |
Why?
|
| Physicians | 2 | 2020 | 428 | 0.750 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2020 | 29 | 0.700 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2011 | 88 | 0.680 |
Why?
|
| Delivery of Health Care | 2 | 2021 | 419 | 0.670 |
Why?
|
| Staphylococcus aureus | 4 | 2022 | 157 | 0.670 |
Why?
|
| Survivors | 1 | 2020 | 148 | 0.670 |
Why?
|
| Burnout, Professional | 1 | 2020 | 118 | 0.590 |
Why?
|
| Infection Control | 5 | 2024 | 92 | 0.580 |
Why?
|
| Patient Safety | 1 | 2020 | 235 | 0.560 |
Why?
|
| Humans | 50 | 2024 | 58880 | 0.560 |
Why?
|
| Quality of Health Care | 1 | 2020 | 513 | 0.500 |
Why?
|
| Immunocompromised Host | 2 | 2013 | 93 | 0.490 |
Why?
|
| Hand Hygiene | 1 | 2014 | 8 | 0.480 |
Why?
|
| Retrospective Studies | 16 | 2024 | 5922 | 0.480 |
Why?
|
| Disease Outbreaks | 3 | 2024 | 105 | 0.470 |
Why?
|
| Caliciviridae Infections | 1 | 2013 | 4 | 0.430 |
Why?
|
| Norovirus | 1 | 2013 | 6 | 0.430 |
Why?
|
| Gastroenteritis | 1 | 2013 | 10 | 0.430 |
Why?
|
| Pneumonia, Viral | 4 | 2020 | 198 | 0.420 |
Why?
|
| Length of Stay | 4 | 2023 | 760 | 0.410 |
Why?
|
| United States | 16 | 2024 | 7441 | 0.410 |
Why?
|
| Hospitalization | 9 | 2024 | 1272 | 0.380 |
Why?
|
| Seasons | 2 | 2020 | 129 | 0.380 |
Why?
|
| Myocarditis | 1 | 2011 | 61 | 0.350 |
Why?
|
| Behavior | 1 | 2010 | 38 | 0.340 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2010 | 29 | 0.340 |
Why?
|
| Motivation | 1 | 2012 | 266 | 0.330 |
Why?
|
| Hospital Mortality | 3 | 2021 | 840 | 0.330 |
Why?
|
| Respiratory Insufficiency | 2 | 2019 | 148 | 0.330 |
Why?
|
| Anti-Infective Agents | 2 | 2021 | 138 | 0.320 |
Why?
|
| Surgical Wound Infection | 1 | 2010 | 105 | 0.320 |
Why?
|
| Methicillin Resistance | 1 | 2008 | 20 | 0.300 |
Why?
|
| Adult | 14 | 2024 | 15609 | 0.300 |
Why?
|
| Clostridium Infections | 2 | 2022 | 46 | 0.300 |
Why?
|
| Ethanol | 1 | 2010 | 304 | 0.270 |
Why?
|
| Epidemiologists | 1 | 2024 | 2 | 0.240 |
Why?
|
| Personal Protective Equipment | 1 | 2024 | 28 | 0.230 |
Why?
|
| Resuscitation Orders | 1 | 2024 | 46 | 0.220 |
Why?
|
| Data Collection | 1 | 2024 | 382 | 0.210 |
Why?
|
| Treatment Outcome | 8 | 2017 | 5100 | 0.200 |
Why?
|
| Aged | 12 | 2024 | 13221 | 0.200 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 68 | 0.190 |
Why?
|
| Anaphylaxis | 1 | 2022 | 40 | 0.190 |
Why?
|
| Health Facilities | 1 | 2021 | 43 | 0.190 |
Why?
|
| Mandatory Programs | 1 | 2021 | 19 | 0.190 |
Why?
|
| Federal Government | 1 | 2021 | 20 | 0.180 |
Why?
|
| Legionnaires' Disease | 1 | 2020 | 8 | 0.180 |
Why?
|
| Masks | 1 | 2021 | 20 | 0.180 |
Why?
|
| Blood Culture | 1 | 2020 | 12 | 0.180 |
Why?
|
| Local Government | 1 | 2021 | 12 | 0.180 |
Why?
|
| State Government | 1 | 2021 | 32 | 0.180 |
Why?
|
| Fluoroquinolones | 2 | 2022 | 29 | 0.180 |
Why?
|
| Coinfection | 1 | 2021 | 44 | 0.180 |
Why?
|
| Drug Resistance, Microbial | 1 | 2020 | 44 | 0.180 |
Why?
|
| Antimicrobial Stewardship | 1 | 2020 | 14 | 0.180 |
Why?
|
| Microbiological Techniques | 1 | 2020 | 6 | 0.180 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2020 | 26 | 0.180 |
Why?
|
| Health Personnel | 1 | 2024 | 337 | 0.180 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2020 | 28 | 0.180 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 44 | 0.170 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2022 | 80 | 0.170 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2010 | 49 | 0.170 |
Why?
|
| Aged, 80 and over | 8 | 2024 | 5046 | 0.170 |
Why?
|
| Viruses | 1 | 2020 | 79 | 0.170 |
Why?
|
| Communicable Diseases | 1 | 2020 | 81 | 0.170 |
Why?
|
| International Classification of Diseases | 1 | 2020 | 142 | 0.170 |
Why?
|
| Superinfection | 2 | 2010 | 10 | 0.160 |
Why?
|
| Academic Medical Centers | 2 | 2012 | 312 | 0.160 |
Why?
|
| Calcitonin | 1 | 2017 | 16 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 186 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 701 | 0.130 |
Why?
|
| Alcoholism | 1 | 2019 | 306 | 0.130 |
Why?
|
| Female | 12 | 2020 | 30581 | 0.130 |
Why?
|
| Middle Aged | 11 | 2020 | 16134 | 0.130 |
Why?
|
| Risk Assessment | 4 | 2022 | 1893 | 0.130 |
Why?
|
| Male | 12 | 2020 | 27286 | 0.120 |
Why?
|
| Hygiene | 1 | 2014 | 11 | 0.120 |
Why?
|
| Sepsis | 2 | 2019 | 278 | 0.120 |
Why?
|
| Risk Factors | 3 | 2020 | 4975 | 0.110 |
Why?
|
| Antiviral Agents | 2 | 2022 | 314 | 0.110 |
Why?
|
| Drug Utilization | 1 | 2015 | 223 | 0.110 |
Why?
|
| Health Policy | 2 | 2024 | 184 | 0.100 |
Why?
|
| Age Distribution | 2 | 2010 | 261 | 0.100 |
Why?
|
| Lecithin Cholesterol Acyltransferase Deficiency | 1 | 2011 | 2 | 0.100 |
Why?
|
| Phosphatidylcholine-Sterol O-Acyltransferase | 1 | 2011 | 6 | 0.100 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2017 | 560 | 0.100 |
Why?
|
| Homozygote | 1 | 2011 | 116 | 0.090 |
Why?
|
| Peer Group | 1 | 2012 | 95 | 0.090 |
Why?
|
| Gentamicins | 1 | 2010 | 22 | 0.090 |
Why?
|
| Mutation, Missense | 1 | 2011 | 179 | 0.090 |
Why?
|
| Immune Sera | 1 | 2010 | 35 | 0.090 |
Why?
|
| Sterilization | 1 | 2010 | 16 | 0.090 |
Why?
|
| Catheter-Related Infections | 1 | 2010 | 40 | 0.090 |
Why?
|
| Public Health | 1 | 2012 | 180 | 0.090 |
Why?
|
| Catheters, Indwelling | 1 | 2010 | 63 | 0.090 |
Why?
|
| Surgical Instruments | 1 | 2010 | 40 | 0.090 |
Why?
|
| Prognosis | 2 | 2019 | 1561 | 0.090 |
Why?
|
| Operating Rooms | 1 | 2010 | 53 | 0.080 |
Why?
|
| New England | 1 | 2010 | 267 | 0.080 |
Why?
|
| Myocardium | 1 | 2011 | 261 | 0.080 |
Why?
|
| Administration, Oral | 2 | 2023 | 343 | 0.080 |
Why?
|
| Heart | 1 | 2011 | 274 | 0.080 |
Why?
|
| Renal Dialysis | 1 | 2010 | 184 | 0.080 |
Why?
|
| Trauma Centers | 1 | 2010 | 120 | 0.080 |
Why?
|
| Surgical Procedures, Operative | 1 | 2010 | 139 | 0.080 |
Why?
|
| Methicillin | 1 | 2008 | 4 | 0.080 |
Why?
|
| Orthomyxoviridae | 1 | 2008 | 26 | 0.080 |
Why?
|
| Bacteriological Techniques | 1 | 2008 | 28 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 211 | 0.080 |
Why?
|
| Echocardiography | 1 | 2011 | 455 | 0.070 |
Why?
|
| Culture Media | 1 | 2008 | 77 | 0.070 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 244 | 0.070 |
Why?
|
| Influenza Vaccines | 1 | 2008 | 88 | 0.070 |
Why?
|
| Chronic Disease | 1 | 2010 | 729 | 0.070 |
Why?
|
| Young Adult | 2 | 2014 | 4279 | 0.060 |
Why?
|
| Hospitals | 2 | 2020 | 373 | 0.060 |
Why?
|
| Strategic Stockpile | 1 | 2024 | 1 | 0.060 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2024 | 22 | 0.060 |
Why?
|
| Time Factors | 2 | 2010 | 3544 | 0.060 |
Why?
|
| Disaster Planning | 1 | 2024 | 51 | 0.060 |
Why?
|
| Adolescent | 2 | 2020 | 5871 | 0.060 |
Why?
|
| Information Dissemination | 1 | 2024 | 113 | 0.050 |
Why?
|
| Cephalosporins | 1 | 2022 | 16 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 2444 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2024 | 325 | 0.050 |
Why?
|
| Macrolides | 1 | 2022 | 38 | 0.050 |
Why?
|
| Oseltamivir | 1 | 2022 | 34 | 0.050 |
Why?
|
| Legionella pneumophila | 1 | 2020 | 10 | 0.050 |
Why?
|
| Blood-Borne Pathogens | 1 | 2020 | 12 | 0.040 |
Why?
|
| Immunity, Humoral | 1 | 2020 | 41 | 0.040 |
Why?
|
| Streptococcus pneumoniae | 1 | 2020 | 59 | 0.040 |
Why?
|
| Comorbidity | 1 | 2024 | 1084 | 0.040 |
Why?
|
| Forecasting | 1 | 2021 | 218 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2015 | 551 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2020 | 57 | 0.040 |
Why?
|
| Communication | 1 | 2024 | 531 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2020 | 176 | 0.040 |
Why?
|
| Pneumonia, Aspiration | 1 | 2019 | 17 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 432 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2020 | 498 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 159 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2015 | 2429 | 0.040 |
Why?
|
| Inpatients | 1 | 2020 | 290 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 1020 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 1090 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2020 | 830 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 418 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2014 | 1441 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2022 | 1461 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2016 | 58 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 925 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 738 | 0.030 |
Why?
|
| Nursing Homes | 1 | 2020 | 663 | 0.030 |
Why?
|
| Hospital Costs | 1 | 2015 | 118 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1202 | 0.030 |
Why?
|
| Disease Progression | 1 | 2017 | 1030 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 2042 | 0.030 |
Why?
|
| Biomarkers | 1 | 2017 | 1199 | 0.030 |
Why?
|
| Corneal Opacity | 1 | 2011 | 4 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2011 | 34 | 0.020 |
Why?
|
| Apolipoprotein A-I | 1 | 2011 | 22 | 0.020 |
Why?
|
| Proteinuria | 1 | 2011 | 37 | 0.020 |
Why?
|
| Lipoproteins, HDL | 1 | 2011 | 36 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2011 | 189 | 0.020 |
Why?
|
| Endocarditis, Bacterial | 1 | 2010 | 29 | 0.020 |
Why?
|
| Cholesterol | 1 | 2011 | 256 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2011 | 394 | 0.020 |
Why?
|
| Heparin | 1 | 2010 | 113 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 402 | 0.020 |
Why?
|
| Equipment Design | 1 | 2010 | 313 | 0.020 |
Why?
|
| Shock, Septic | 1 | 2010 | 90 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2011 | 1576 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 2010 | 295 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2010 | 478 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2008 | 254 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2010 | 485 | 0.020 |
Why?
|
| Vaccination | 1 | 2008 | 333 | 0.020 |
Why?
|
| Massachusetts | 1 | 2010 | 2078 | 0.010 |
Why?
|
| Infant | 1 | 2008 | 1509 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2008 | 2316 | 0.010 |
Why?
|
| Animals | 1 | 2020 | 19498 | 0.010 |
Why?
|
| Pregnancy | 1 | 2008 | 2334 | 0.010 |
Why?
|